Intrinsiqs

Is Fulcrum Therapeutics, Inc. overvalued?

Fulcrum Therapeutics, Inc. (FULC) — key valuation metrics and fundamentals.

No verdict
Price
$3.74
Fair value
Current P/E
Normal P/E
Market cap
$285.4M
Dividend yield
0.0%
Return on equity
-28.5%
Sector
Healthcare

See the full interactive analysis →

Fair value compares FULC's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.